PUBLICATIONS

  1. Garvin, RA. Relaxin levels in matched sera and CSF from subjects with multiple sclerosis. Ital J Anat Embry, (in print, 2018).

  2. Garvin, RA. Treatment with relaxin reduces disease symptoms and enhances neuroprotection and remyelination in murine experimental autoimmune encephalomyelitis. Ital J Anat Embry, Vol. 123, n. 1: 64-79, 2018.

  3. Garvin, RA and Burns, A. Serum Relaxin Levels in Subjects with Multiple Sclerosis. Ital J Anat Embry, p. 51-59, Jun. 2016. ISSN 2038-5129. Available at: http://www.fupress.net/index.php/ijae/article/view/18344. Date accessed: 01 Jul. 2016. doi:10.13128/IJAE-18344.

  4. Garvin, RA. Treatment with Relaxin Reduces Severity, Decreases Chemokine Receptors and Pro-Inflammatory cytokines in Experimental Autoimmune Encephalomyelitis Mult Scler September 2015 vol. 21 no. 11 suppl pp:138-139. doi: 10.1177/1352458515602642

  5. Garvin, RA. Elevated Phospholipid Transfer Protein in Subjects with Multiple Sclerosis, Journal of Lipids, vol. 2015, Article ID 518654, 2015. doi:10.1155/2015/518654

  6. Garvin, RA and Burns, A. A pilot study of relaxin in multiple sclerosis: diagnostic and therapeutic implications Mult Scler, October 2011; vol. 17, 10 suppl: pp. S507-S524, P1131.

   7. Garvin RA, Swank RL, Fleck A, Phospholipid Transfer Proteins in Multiple Sclerosis, Proceedings of the Association of Clinical Biochemist,           (abs) 1991

  13. Swank RL, Garvin RA, Unusual Plasma Protein in Multiple Sclerosis, Proceedings of the Society of Experimental Biology and Medicine,                 National Meeting, April 1-5, 1990, Vol. 4, No. 3, pp 2492

PRESENTATIONS

  1. “Treatment with Relaxin Reduces the Severity, Decreases Chemokines, Chemokine Receptors and Pro-Inflammatory cytokines in Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice” European Committee into Treatment and Research of Multiple Sclerosis 2015. Barcelona, Spain

  2. "Relaxin and Multiple Sclerosis" Biology of Relaxin and its Role in the Human: 6th International Conference on Relaxin and Related Peptides. 2012 Florence, Italy

  3. “A pilot study of relaxin in multiple sclerosis: diagnostic and therapeutic implications” European Committee into Treatment and Research of Multiple Sclerosis 2011. Amsterdam, Netherlands

  4. “PLTP abnormalities in subjects with multiple sclerosis” Regional Meeting: The Royal Society of Medicine 1999. RSM 1 Wimpole Street, London, UK.

 

PATENTS:

  1. Garvin RA and Burns A, Novel Therapy, 2015 UK N:1516068.2

  2. Garvin RA and Burns A, Relaxin Proteins For Use In The Diagnosis, Prevention or Treatment of Multiple Sclerosis UK 1110833.9

  3. Garvin RA and Burns A, Ergonomic Laboratory Filter Basket. PCT/GB2010/000691

  4. Garvin RA, Burns A, Laboratory Sample Container Closure System US 13/267,345

  5. Garvin RA, Swank RL, Diagnostic Test for Multiple Sclerosis, US 91.908712.2 PCT/US90/07109, 11-1992

BVBIOMED LTD

© 2019 BVBiomed Ltd.

Proudly created with Wix.com

BVBiomed Ltd.

Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford, UK OX4 4GA

Novel Drug Discovery